Benzamide or benzamine compounds useful as anticancer agents for the treatment of human cancers

A pharmaceutical composition comprising a small molecule anti-cancer compound of Formula I-f:

• wherein:
• X1 is selected from the group consisting of H, F, CN, NH2, NO2, N3, and SO2Me;
• n=1, 2, or 3;
• L2 is selected from the group consisting of S, O, NH, CHOH, C═O, —O(CH2)—, —S(CH2)—, —(CH2)O—, and —(CH2)S—;
• R1 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl, and acyloxyalkyl;
• R1 and R2 may optionally form a ring, such that R1-R2 consists of a three to six subunit chain comprising subunits independently selected from the group consisting of (CR7R8), NR9, O, and S;
• R1 and R3 may optionally form a ring, such that R1-R3 comprises —(CR10R11)m, where m=2, 3, 4 or 5;
• R2 is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl, and acyloxyalkyl;
• R2 and R4 may optionally form a ring, such that R2-R4 consists of a one to four subunit chain comprising subunits independently selected from the group consisting of —(CR12R13);
• R2 may simultaneously form a ring with R1 as described above;
• R3 is selected from the group consisting of H, D, F, Me, and Et;
• R4 is selected from the group consisting of H, Me, CD3, CF3, Et, i-Pr, cyclopropyl, and C2-C6 alkynyl;
• R7 and R8 are independently selected from the group consisting of H, D, F, Me, Et, OR, and NR2;
• wherein R is selected from the group consisting of H, Me, and Et;
• R9 is selected from the group consisting of H, Me, Et, isopropyl, and cyclopropyl;
• R10 and R11 are independently selected from the group consisting of H, D, F, Me, Et, OR, and NR2;
• wherein R is selected from the group consisting of H, Me, and Et;
• R12 and R13 are independently selected from the group consisting of H, D, F, Me, and Et;
• and
• R14 and R15 can be attached at any available position on the aromatic ring and are selected from the group consisting of H, D, F, Cl, Br, CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, OR, NR2, NO2, N3, CN, CO2R, CO2NR2, SR, alkylacyl and arylacyl;
• wherein R is independently selected from the group consisting of H, Me, Et, isopropyl, cyclopropyl, propargyl, and acyl;
• such that all possible stereoisomers, including optically active isomers, are included whenever stereogenic centers are present;
• or a pharmaceutically acceptable salt, prodrug, active metabolite, or solvate thereof,
• wherein the pharmaceutical composition comprises a therapeutic amount of the compound and a pharmaceutically acceptable carrier.